Lacripep for Neurotrophic Keratopathy
What You Need to Know Before You Apply
What is the purpose of this trial?
Objective: To evaluate the safety of Lacripep 4 μM Ophthalmic Solution and its effect on the ocular surface, visual function, corneal sensitivity, and quality of life of subjects with Stage 1 NK.
Who Is on the Research Team?
Marc Odrich, MD
Principal Investigator
TearSolutions CMO
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Run-in
Participants receive open-label vehicle ophthalmic solution
Treatment
Participants are randomized to receive either Lacripep 4 μM Ophthalmic Solution or vehicle ophthalmic solution, dosed TID in both eyes
Open-label Extension
Participants receive open-label Lacripep 4 μM Ophthalmic Solution, dosed TID in both eyes
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Lacripep
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Find a Clinic Near You
Who Is Running the Clinical Trial?
TearSolutions, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.